Curis Lifesciences Limited (NSE:CURIS)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
Drug Delivery Systems	606.29M	496.32M	355.56M	354.49M	237.45M
Total	606.29M	496.32M	355.56M	354.49M	237.45M

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
India	477.88M	340.56M	333.70M	72.48M
Export	131.00K	2.00M	3.56M	-
Other	13.31M	13.00M	17.23M	-
Rwanda	-	-	-	43.53M
Myanmar	-	-	-	19.07M
Kenya	-	-	-	16.14M
Uzbekistan	-	-	-	398.00K
Malawi	-	-	-	6.45M
United Kingdom	-	-	-	2.67M
Nigeria	-	-	-	1.80M
Sierra Leone	-	-	-	11.42M
Tazakistan	-	-	-	4.38M
Peru	-	-	-	1.35M
Mali	-	-	-	4.80M
Afghanistan	-	-	-	562.00K
Panama	-	-	-	3.19M
Angola	-	-	-	11.05M
Barbadosa	-	-	-	1.94M
DRC	-	-	-	12.59M
Total	491.32M	355.56M	354.49M	213.80M

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error